Division of Gastroenterology and Hepatology, Department of Internal Medicine Thomas Jefferson University Hospital, Philadelphia, PA, USA.
J Clin Gastroenterol. 2011 Oct;45(9):824-7. doi: 10.1097/MCG.0b013e318211f96f.
We report a retrospective analysis of patients with malignant biliary obstruction in whom a newly released fully silicon-covered, WallFlex, self-expandable metal stent (CSEMS) was placed for biliary decompression.
Between March, 2009 and March, 2010, all patients with obstructive jaundice secondary to pancreatic cancer underwent placement of a CSEMS, regardless of resectability. A CSEMS was placed across the malignant stricture. These patients were then staged for their cancer by computed tomography, magnetic resonance imaging, and/or endoscopic ultrasound-guided fine-needle aspiration. Patient found to have resectable cancer were offered a pancreaticoduodenectomy.
We identified 88 patients with pancreatic cancer who received a CSEMS. Forty patients were deemed resectable and underwent surgery. Pancreaticoduodenectomy was performed in 34 of 40 patients. The CSEMS was easily removed at the time of surgical resection without any complications. The 44 unresected patients with covered SEMS were followed for a mean of 4.2 months (range, 1 to 13). The patency rate for stents was 97% at 12 months. Immediate procedural complications included post-endoscopic retrograde cholangiopancreatography pancreatitis (n=9) and duodenal perforation (n=2). Four patients (5%) had migration and 3 (3%) had stent occlusion. There were no cases of cholecystitis during the follow-up. The patients who presented with stent migration or occlusion underwent stent revision.
Placement of the newly available CSEMS can be used to effectively and safely treat biliary obstructions from pancreatic carcinoma. We recommend that the CSEMS be used as an initial intervention to relieve malignant biliary obstruction, even in patients whose surgical resectability status is uncertain.
我们报告了一项回顾性分析,研究了在恶性胆道梗阻患者中放置新型全硅覆盖、WallFlex 自膨式金属支架(CSEMS)进行胆道减压的情况。
2009 年 3 月至 2010 年 3 月期间,所有因胰腺癌引起的阻塞性黄疸患者均接受了 CSEMS 治疗,无论其可切除性如何。CSEMS 被放置在恶性狭窄处。然后,通过计算机断层扫描、磁共振成像和/或内镜超声引导下细针抽吸对这些患者进行癌症分期。发现可切除癌症的患者被提供胰十二指肠切除术。
我们确定了 88 例接受 CSEMS 治疗的胰腺癌患者。40 例患者被认为是可切除的,并接受了手术。在 40 例患者中,有 34 例进行了胰十二指肠切除术。在手术切除时,CSEMS 很容易被移除,没有任何并发症。44 例未接受手术切除且带有覆盖支架的患者平均随访 4.2 个月(范围为 1 至 13 个月)。支架通畅率在 12 个月时为 97%。即刻手术并发症包括内镜逆行胰胆管造影术后胰腺炎(n=9)和十二指肠穿孔(n=2)。4 例(5%)发生支架迁移,3 例(3%)发生支架阻塞。在随访期间无胆囊炎病例。出现支架迁移或阻塞的患者进行了支架修复。
新型 CSEMS 的放置可有效且安全地治疗胰腺癌引起的胆道梗阻。我们建议将 CSEMS 用作初始干预措施,以缓解恶性胆道梗阻,即使在手术可切除性状态不确定的患者中也是如此。